Skip to content
Precision for Medicine

Announcing the Institute@Precision, a Collaborative Forum for Biopharma Innovation.

iStock-1888883171 iStock-1888883171

Tissue Cross-Reactivity Studies

TCR screening studies or GLP-compliant TCR studies suitable for IND submission

Precision for Medicine’s scientific team can perform TCR screening studies using frozen tissue microarrays or GLP–compliant TCR studies suitable for Investigational New Drug (IND) submission. Guidelines issued by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the development of therapeutic antibodies and related products recommend their testing for tissue cross-reactivity (TCR) on a range of human tissues.

Tailored methodology for biotherapeutic tissue cross-reactivity studies

Precision for Medicine’s unique combination of research services and comprehensive tissue bank form the pillars of our TCR Services.

PFM - Parathyroid TCR

Tissue cross-reactivity study services

Combined with a tailored scientific approach, Precision’s expertise in immunohistochemistry (IHC) assay development for a range of biotherapeutic modalities enables us to deliver high-quality data to our clients in a defined time period.

  • Assay development and optimization
  • Confirmation of tissue antigenicity
  • TCR screening using frozen tissue microarrays for rapid data delivery prior to fully GLP-compliant studies
  • GLP tissue cross-reactivity studies utilizing all 36 required human tissue types
  • Fully automated IHC assays
  • Medicines and Healthcare products Regulatory Agency (MHRA) GLP-certified facility
  • In-house pathology services

Qualified biospecimens for tissue cross-reactivity studies

  • Robust qualification of tissues from procurement to assay use

  • Non-GLP tissue microarray (TMA)

  • GLP full-face sections of 36 human tissue types

Frozen-tissue-microarray

Guide to successfully conducting tissue cross-reactivity studies

Whitepaper

Guide to Successfully Conducting Tissue Cross-Reactivity Studies

Download Whitepaper
Guide to Successfully Conducting Tissue Cross-Reactivity Studies

Tissue types available for GLP TCR studies

Precision for Medicine is a leading supplier of well-characterized biospecimens for research—all collected through a global network of healthcare specialists. All human tissues recommended for TCR testing by the FDA and the EMA are fully consented for commercial research, and available from at least 3 male and 3 female donors.

Tissue types are available from multiple male and female donors

Adrenal gland lleum Prostate
Bladder Kidney—glomerulus and tubule Skeletal muscle
Blood cells Liver Skin
Blood vessel endothelium Lung—bronchus and parenchyma Spinal cord
Bone marrow Lymph node Spleen
Breast Ovary Stomach
Cerebellum Pancreas Testis
Cerebral cortex Parathyroid gland Thymus
Colon Parotid salivary gland Thyroid gland
Eye Peripheral nerve Tonsil
Fallopian tube Pituitary gland Ureter
Heart Placenta Uterus—cervix and endometrium

Precision’s 3-phase approach to TCR testing

Tissue-cross-reactivity_Diagram-1

Learn more about Precision’s tissue cross-reactivity capabilities

Brochure

Brochure: GLP Tissue Cross Reactivity Testing

Download Brochure
Brochure: GLP Tissue Cross Reactivity Testing

Integrating biomarker and clinical trial data

To help researchers understand and interpret biomarker assay data in the context of other assays as well as the clinical trial data, Precision manages all assay data using our proprietary QuartzBio® Translational Informatics platform.

Learn more about the sample management, informatics, and computational capabilities of QuartzBio®.

Global reach, multi-site support

We provide TCR study services that support preclinical research conducted anywhere in the world, with specialty labs located in North America and Europe.

Working with Precision

Precision’s specialty lab scientists take collaborative and consultative approaches to projects and can provide recommendations on biomarker assay strategies and implementation. Services can be provided individually or as part of a comprehensive therapeutic development package including biomarker assays and clinical trials.

Discover the Precision blog

Read our blog to gain more insights and discover work that Precision has supported.

Read: Investor Relations, Clinical Operations, and the Future of Biotech Financing Investor Relations, Clinical Operations, and the Future of Biotech Financing

Clinical Trials - Translational Research - Early Phase Research

Investor Relations, Clinical Operations, and the Future of Biotech Financing

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548862, hs_child_table_id=0, hs_updated_at=1716454315513, hs_published_at=1761062733198, description=Teresa is a respected business development strategist, building successful clinical programs for clients in Massachusetts. She is an innovator of fresh approaches to biomarker planning, translational solutions, and clinical study design. Her experience spans the execution of Phase 1-4 clinical trials, specialty lab services, companion and in vitro diagnostic strategies, and biomarker data management., avatar=Image{width=700,height=700,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Teresa-Pokladowski-300x300.png',altText='Teresa-Pokladowski-300x300',fileId=168135942975}, linkedin=https://www.linkedin.com/in/teresapokladowski/, lastname=Pokladowski, hs_initial_published_at=1713363230550, hs_created_by_user_id=5166971, hs_created_at=1713362443509, hs_is_edited=false, hs_deleted_at=0, name=Teresa, job=Regional Vice President, Clinical Business Solutions, North America, slug=teresa-pokladowski, hs_updated_by_user_id=26433386}, second={hs_id=197608580658, hs_child_table_id=0, hs_updated_at=1760465121471, hs_published_at=1761062733198, description=Hannah Dereseiwicz is a strategic force in investor relations, helping biotech innovators translate complex science into compelling narratives that drive engagement and growth. With a track record spanning commercial launches, M&A activity, and high-stakes communications, she brings clarity, confidence, and momentum to every stage of a company’s journey. Hannah’s approach is defined by the three A’s—ambitious, approachable, and authentic—making her a trusted partner for teams looking to elevate their story and connect with the audiences that matter most., avatar=Image{width=636,height=476,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Hannah%20Deresiewicz.webp',altText='Hannah Deresiewicz',fileId=197608718507}, lastname=Deresiewicz, hs_initial_published_at=1760465283803, hs_created_by_user_id=26433386, hs_created_at=1760464991513, hs_is_edited=false, hs_deleted_at=0, name=Hannah, job=Executive Vice President, Managing Director Precision AQ – Investor Relations & External Communications, slug=hannah-deresiewicz, hs_updated_by_user_id=26433386}, third={}})
  • Teresa P. avatar

    Teresa P.

  • Hannah D. avatar

    Hannah D.

Discover
Read: The Immune System's Secret Language: Unlocking Cellular Communication The Immune System's Secret Language: Unlocking Cellular Communication

Translational Research - Lab Services

The Immune System's Secret Language: Unlocking Cellular Communication

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778858, hs_child_table_id=0, hs_updated_at=1754641583843, hs_published_at=1761062733198, description=Rob Maiale is a marketing strategist and creative technologist with 17 years of experience turning complex ideas into growth. He currently leads content strategy, where he transforms insights from Precision experts into market-shaping narratives that drive the advancement of next-generation therapies.  Rob’s career spans journalism, advertising, and brand storytelling, with a through-line of making the meaningful memorable. His work blends creative strategy with emerging AI tools to help Precision stay ahead of the curve—and above the noise., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/rob.png',altText='rob',fileId=194099000843}, linkedin=https://www.linkedin.com/in/rob-maiale/, hs_name=, hs_path=, lastname=Maiale, hs_initial_published_at=1758208027822, hs_created_at=1709645745089, hs_is_edited=false, hs_deleted_at=0, name=Rob, position=Associate Director, Digital Content & Inbound Marketing, job=, slug=rob-maiale, email=, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Rob Maiale avatar

    Rob Maiale

Discover
Read: How AI & Biomarkers Are Reshaping the Next Frontier in Drug Development How AI & Biomarkers Are Reshaping the Next Frontier in Drug Development

Translational Research - Biomarkers - Oncology

How AI & Biomarkers Are Reshaping the Next Frontier in Drug Development

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778858, hs_child_table_id=0, hs_updated_at=1754641583843, hs_published_at=1761062733198, description=Rob Maiale is a marketing strategist and creative technologist with 17 years of experience turning complex ideas into growth. He currently leads content strategy, where he transforms insights from Precision experts into market-shaping narratives that drive the advancement of next-generation therapies.  Rob’s career spans journalism, advertising, and brand storytelling, with a through-line of making the meaningful memorable. His work blends creative strategy with emerging AI tools to help Precision stay ahead of the curve—and above the noise., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/rob.png',altText='rob',fileId=194099000843}, linkedin=https://www.linkedin.com/in/rob-maiale/, hs_name=, hs_path=, lastname=Maiale, hs_initial_published_at=1758208027822, hs_created_at=1709645745089, hs_is_edited=false, hs_deleted_at=0, name=Rob, position=Associate Director, Digital Content & Inbound Marketing, job=, slug=rob-maiale, email=, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Rob Maiale avatar

    Rob Maiale

Discover